Overview
Dr. Mettu, MD is a fellowship-trained ophthalmologist, specializing in the diagnosis, treatment, and research of macular diseases. His clinical practice focuses on the medical treatment of diabetic retinopathy, age-related macular degeneration, and retinal vascular diseases. He has an active clinical and laboratory research program at the Duke Center for Macular Diseases as part of the National Institutes of Health-sponsored K12 program. Dr. Mettu is actively involved in clinical trials of new therapies for macular diseases. He is developing novel imaging technologies that will facilitate customized treatment plans for patients with diabetic macular edema and age-related macular degeneration. Dr. Mettu is a recipient of the prestigious Heed Foundation Fellowship and the Isbey Award for excellence in clinical care, ethics, and research.
Current Appointments & Affiliations
Recent Publications
A Deep-Learning Algorithm to Predict Short-Term Progression to Geographic Atrophy on Spectral-Domain Optical Coherence Tomography.
Journal Article JAMA Ophthalmol · November 1, 2023 IMPORTANCE: The identification of patients at risk of progressing from intermediate age-related macular degeneration (iAMD) to geographic atrophy (GA) is essential for clinical trials aimed at preventing disease progression. DeepGAze is a fully automated a ... Full text Link to item CiteFluorescein CorneoGraphy (FCG): Use of a repurposed fluorescein imaging technique to objectively standardize corneal staining.
Journal Article Ocul Surf · January 2023 Punctate epithelial erosion (PEE) is a corneal sign of dry eye disease (DED), which is observable via staining with fluorescein on slit lamp as a standard of clinical practice and clinical research. There are currently many limitations for detecting PEE, s ... Full text Link to item CiteIntravitreal Delivery of rAAV2tYF-CB-hRS1 Vector for Gene Augmentation Therapy in Patients with X-Linked Retinoschisis: 1-Year Clinical Results.
Journal Article Ophthalmol Retina · December 2022 PURPOSE: To evaluate the safety and efficacy of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin (RS1), in individuals with retinal disease caused by mutations in the RS1 gene. DESIGN: Open-label, phase I/II dose-escal ... Full text Link to item CiteRecent Grants
Regulation of Macrophage-Mediated Neovascular Remodeling in Neovascular AMD
ResearchPrincipal Investigator · Awarded by BrightFocus Foundation · 2021 - 2023SPIAM-202 - Age-Related Macular Degeneration with Geographic Atrophy
Clinical TrialPrincipal Investigator · Awarded by Stealth BioTherapeutics · 2019 - 2023An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects with Intermediate Age-Related Macular Degeneration
Clinical TrialCore PI · Awarded by Stealth BioTherapeutics · 2016 - 2022View All Grants